JPMorgan raised the firm’s price target on Cogent Biosciences (COGT) to $21 from $19 and keeps an Overweight rating on the shares. The firm says its physician survey data suggests enthusiasm for the potential of bezuclastinib in advanced systemic mastocytosis and non-advanced. The firm believes safety concerns for the program are overblown and that bezuclastinib has the potential to “navigate a clean therapeutic window across indications.” It sees “plenty of upside” in Cogent shares on only the advanced systemic mastocytosis and gastrointestinal stromal tumors populations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing
- Cogent Biosciences reports Q3 EPS (64c), consensus (57c)
- COGT Upcoming Earnings Report: What to Expect?
- Cogent selloff on ‘old news’ is ‘unwarranted,’ says Citi
- Cogent data has positive read-through to Blueprint, says Barclays